Company overview
ProImmune provides specialized reagents and services for T-cell immunology research, including ProVE SL Self-Loading MHC Class I Monomers for flexible antigen-specific CD8+ T-cell detection across over 50 HLA alleles. They offer REVEAL for rapid epitope discovery and collaborate on tools like Ankyrons for high-containment infectious disease studies. These products support pharmaceutical R&D in vaccine development, immunotherapy, and immune monitoring.
ProImmune is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents partner serving United States & Americas. Core focus areas include proimmune, mhc monomers, t-cell reagents, epitope discovery, immunology tools.
Industry categories: Life Science Reagents. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.proimmune.com
- Categories
- Life Science Reagents
- Markets served
- United States & Americas
- Keywords
- proimmune, mhc monomers, t-cell reagents, epitope discovery, immunology tools
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What MHC reagents does ProImmune offer for T-cell analysis?
- ProImmune offers ProVE SL Self-Loading MHC Class I Monomers, supplied as empty, biotinylated molecules for over 50 HLA alleles including HLA-A, B, C, non-canonical, and mouse H-2, enabling quick peptide loading for CD8+ T-cell detection.
- What services does ProImmune provide for epitope discovery?
- ProImmune's REVEAL service, combined with ProVE platform, enables rapid epitope discovery for immune research applications.
- Does ProImmune support infectious disease or high-containment research?
- Yes, ProImmune collaborates with institutions like UTMB Galveston National Laboratory to validate Ankyrons for detecting and studying viral proteins in high-containment settings for vaccines and therapeutics.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
